MAM01/ATRC-501 is a monoclonal antibody entering preclinical development.
Under the agreement, Gates MRI will lead the development of MAM01/ATRC-501 and receive commercial rights in GAVI-eligible countries.
Atreca will retain commercial rights in the U.S., Europe, and parts of Asia.
MAM01/ATRC-501 is an engineered version of a human monoclonal antibody generated following vaccination with Mosquirix and identified via Atreca's discovery platform.
MAM01/ATRC-501 targets the malaria circumsporozoite protein (CSP) and has been shown to protect animals against malaria infection in multiple in vivo mouse studies.
Price Action: BCEL shares are up 4.96% at $5.50 during the premarket session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.